Literature DB >> 22013041

The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.

Mawuena Binka1, Marcel Ooms, Myeika Steward, Viviana Simon.   

Abstract

The APOBEC3 family comprises seven cytidine deaminases (APOBEC3A [A3A] to A3H), which are expressed to various degrees in HIV-1 susceptible cells. The HIV-1 Vif protein counteracts APOBEC3 restriction by mediating its degradation by the proteasome. We hypothesized that Vif proteins from various HIV-1 subtypes differ in their abilities to counteract different APOBEC3 proteins. Seventeen Vif alleles from seven HIV-1 subtypes were tested for their abilities to degrade and counteract A3G, A3F, and A3H haplotype II (hapII). We show that most Vif alleles neutralize A3G and A3F efficiently but display differences with respect to the inhibition of A3H hapII. The majority of non-subtype B Vif alleles tested presented some activity against A3H hapII, with two subtype F Vif variants being highly effective in counteracting A3H hapII. The residues required for activity were mapped to two residues in the amino-terminal region of Vif (positions 39F and 48H). Coimmunoprecipitations showed that these two amino acids were necessary for association of Vif with A3H hapII. These findings suggest that the A3H hapII binding site in Vif is distinct from the regions important for A3G and A3F recognition and that it requires specific amino acids at positions 39 and 48. The differential Vif activity spectra, especially against A3H hapII, suggest adaptation to APOBEC3 repertoires representative of different human ancestries. Phenotypic assessment of anti-APOBEC3 activity of Vif variants against several cytidine deaminases will help reveal the requirement for successful replication in vivo and ultimately point to interventions targeting the Vif-APOBEC3 interface.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22013041      PMCID: PMC3255910          DOI: 10.1128/JVI.06082-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  APOBEC3G incorporation into human immunodeficiency virus type 1 particles.

Authors:  Véronique Zennou; David Perez-Caballero; Heinrich Göttlinger; Paul D Bieniasz
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

2.  Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G.

Authors:  Kun Luo; Zuoxiang Xiao; Elana Ehrlich; Yunkai Yu; Bindong Liu; Shu Zheng; Xiao-Fang Yu
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-02       Impact factor: 11.205

Review 3.  Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors.

Authors:  Bryan R Cullen
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

4.  Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G.

Authors:  Bärbel Schröfelbauer; Tilo Senger; Gerard Manning; Nathaniel R Landau
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

5.  Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes.

Authors:  Lubbertus C F Mulder; Marcel Ooms; Susan Majdak; Jordan Smedresman; Caitlin Linscheid; Ariana Harari; Andrea Kunz; Viviana Simon
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

6.  A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity.

Authors:  Anjie Zhen; Tao Wang; Ke Zhao; Yong Xiong; Xiao-Fang Yu
Journal:  J Virol       Date:  2009-11-25       Impact factor: 5.103

Review 7.  Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.

Authors:  John S Albin; Reuben S Harris
Journal:  Expert Rev Mol Med       Date:  2010-01-22       Impact factor: 5.600

8.  Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif.

Authors:  Erez Pery; Kottampatty S Rajendran; Andrew Jay Brazier; Dana Gabuzda
Journal:  J Virol       Date:  2008-12-24       Impact factor: 5.103

9.  Cytidine deamination induced HIV-1 drug resistance.

Authors:  Lubbertus C F Mulder; Ariana Harari; Viviana Simon
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-07       Impact factor: 11.205

Review 10.  HIV-1 Vif, APOBEC, and intrinsic immunity.

Authors:  Ritu Goila-Gaur; Klaus Strebel
Journal:  Retrovirology       Date:  2008-06-24       Impact factor: 4.602

View more
  61 in total

1.  Vif proteins of human and simian immunodeficiency viruses require cellular CBFβ to degrade APOBEC3 restriction factors.

Authors:  Judd F Hultquist; Mawuena Binka; Rebecca S LaRue; Viviana Simon; Reuben S Harris
Journal:  J Virol       Date:  2011-12-28       Impact factor: 5.103

2.  APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.

Authors:  John F Krisko; Nurjahan Begum; Caroline E Baker; John L Foster; J Victor Garcia
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

3.  Accessory genes confer a high replication rate to virulent feline immunodeficiency virus.

Authors:  Ryan M Troyer; Jesse Thompson; John H Elder; Sue VandeWoude
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

4.  Evolutionarily conserved pressure for the existence of distinct G2/M cell cycle arrest and A3H inactivation functions in HIV-1 Vif.

Authors:  Ke Zhao; Juan Du; Yajuan Rui; Wenwen Zheng; Jian Kang; Jingwei Hou; Kang Wang; Wenyan Zhang; Viviana A Simon; Xiao-Fang Yu
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

5.  Single-Strand Consensus Sequencing Reveals that HIV Type but not Subtype Significantly Impacts Viral Mutation Frequencies and Spectra.

Authors:  Jonathan M O Rawson; Daryl M Gohl; Sean R Landman; Megan E Roth; Morgan E Meissner; Tara S Peterson; James S Hodges; Kenneth B Beckman; Louis M Mansky
Journal:  J Mol Biol       Date:  2017-05-11       Impact factor: 5.469

Review 6.  Structural insights for HIV-1 therapeutic strategies targeting Vif.

Authors:  Jason D Salter; Guillermo A Morales; Harold C Smith
Journal:  Trends Biochem Sci       Date:  2014-08-12       Impact factor: 13.807

7.  Characterization of RNA binding and chaperoning activities of HIV-1 Vif protein. Importance of the C-terminal unstructured tail.

Authors:  Dona Sleiman; Serena Bernacchi; Santiago Xavier Guerrero; Franck Brachet; Valéry Larue; Jean-Christophe Paillart; Carine Tisne
Journal:  RNA Biol       Date:  2014-07-22       Impact factor: 4.652

8.  Determinants of efficient degradation of APOBEC3 restriction factors by HIV-1 Vif.

Authors:  Tayyba T Baig; Yuqing Feng; Linda Chelico
Journal:  J Virol       Date:  2014-10-01       Impact factor: 5.103

9.  Vif Proteins from Diverse Human Immunodeficiency Virus/Simian Immunodeficiency Virus Lineages Have Distinct Binding Sites in A3C.

Authors:  Zeli Zhang; Qinyong Gu; Ananda Ayyappan Jaguva Vasudevan; Manimehalai Jeyaraj; Stanislaw Schmidt; Jörg Zielonka; Mario Perković; Jens-Ove Heckel; Klaus Cichutek; Dieter Häussinger; Sander H J Smits; Carsten Münk
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

10.  APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.

Authors:  Chawaree Chaipan; Jessica L Smith; Wei-Shau Hu; Vinay K Pathak
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.